| Visualizaciones | |
|---|---|
| Multicenter Phase I Study of Erdafitinib (JNJ-42756493) Oral Pan-Fibroblast Growth Factor Receptor Inhibitor in Patients with Advanced or Refractory Solid Tumors | 73 |
| enero 2024 | febrero 2024 | marzo 2024 | abril 2024 | mayo 2024 | junio 2024 | julio 2024 | |
|---|---|---|---|---|---|---|---|
| Multicenter Phase I Study of Erdafitinib (JNJ-42756493) Oral Pan-Fibroblast Growth Factor Receptor Inhibitor in Patients with Advanced or Refractory Solid Tumors | 9 | 30 | 3 | 7 | 4 | 11 | 9 |
| Visualizaciones | |
|---|---|
| artconlli_a2019_tabernero_josep_multicenter_phase I_study.pdf | 56 |
| Visualizaciones | |
|---|---|
| Estados Unidos | 32 |
| China | 8 |
| Corea del Sur | 2 |
| Colombia | 1 |
| España | 1 |
| Visualizaciones | |
|---|---|
| Menlo Park | 10 |
| Shanghai | 6 |
| Oakland | 5 |
| San Diego | 4 |
| Ann Arbor | 3 |
| Houston | 2 |
| Atlanta | 1 |
| Barcelona | 1 |
| Boardman | 1 |
| Guangzhou | 1 |